| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
B-Dependent Antiapoptotic Pathway1
Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, M5S 1A8 Canada
Functional inactivation of the von Hippel-Lindau (VHL) tumor suppressor protein pVHL is the cause of the familial VHL disease and the majority of sporadic renal clear cell carcinomas (RCCs). RCCs pose a significant problem for conventional cancer treatment protocols because of their highly recalcitrant characteristics to radio- and/or chemotherapies. In fact, the leading cause of morbidity and mortality of VHL patients is RCC. Recently, global gene profiling of RCC cells has revealed that sensitivity to tumor necrosis factor (TNF)-
-mediated cytotoxicity is pVHL dependent. Here, we report that although RCC cells devoid of functional pVHL (RC3) were resistant to the cytotoxic effects of TNF-
, reconstitution of these RCC cells with wild-type pVHL (WT8) restored their sensitivity to TNF-
cytotoxicity. The major TNF-
-inducible transcription factor nuclear factor (NF)-
B in the nuclear fraction capable of binding NF-
B-binding motifs was significantly increased in RC3 cells. Concordantly, the expression of NF-
B-target antiapoptotic genes c-FLIP, Survivin, c-IAP-1, and cIAP-2, which block the activities of caspases 8 and 3, were dramatically elevated in RC3 cells. Indeed, RC3 cells showed low caspases 8 and 3 activities. These results demonstrate that pVHL facilitates TNF-
-induced cytotoxicity in RCC cells, at least in part, through the down-regulation of NF-
B activity and subsequent attenuation of antiapoptotic proteins c-FLIP, Survivin, c-IAP-1, and c-IAP-2.
This article has been cited by other articles:
![]() |
S. A.J. VAZIRI, D. R. GRABOWSKI, J. HILL, L. R. RYBICKI, R. BURK, R. M. BUKOWSKI, M. K. GANAPATHI, and R. GANAPATHI Inhibition of Proteasome Activity by Bortezomib in Renal Cancer Cells Is p53 Dependent and VHL Independent Anticancer Res, August 1, 2009; 29(8): 2961 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mahajan, V. Dammai, T. Hsu, and A.S. Kraft Hypoxia-inducible factor-2{alpha} regulates the expression of TRAIL receptor DR5 in renal cancer cells Carcinogenesis, September 1, 2008; 29(9): 1734 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sourbier, S. Danilin, V. Lindner, J. Steger, S. Rothhut, N. Meyer, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy Cancer Res., December 15, 2007; 67(24): 11668 - 11676. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Raval, S. Biswas, P. Rayman, K. Biswas, G. Sa, S. Ghosh, M. Thornton, C. Hilston, T. Das, R. Bukowski, et al. TNF-{alpha} Induction of GM2 Expression on Renal Cell Carcinomas Promotes T Cell Dysfunction J. Immunol., May 15, 2007; 178(10): 6642 - 6652. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Kaelin Jr. The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 680s - 684s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. An and M. B. Rettig Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib Mol. Cancer Ther., January 1, 2007; 6(1): 61 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Cummins, E. Berra, K. M. Comerford, A. Ginouves, K. T. Fitzgerald, F. Seeballuck, C. Godson, J. E. Nielsen, P. Moynagh, J. Pouyssegur, et al. Prolyl hydroxylase-1 negatively regulates I{kappa}B kinase-beta, giving insight into hypoxia-induced NF{kappa}B activity PNAS, November 28, 2006; 103(48): 18154 - 18159. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. An and M. B. Rettig Mechanism of von Hippel-Lindau Protein-Mediated Suppression of Nuclear Factor kappa B Activity Mol. Cell. Biol., September 1, 2005; 25(17): 7546 - 7556. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Kosari, A. S. Parker, D. M. Kube, C. M. Lohse, B. C. Leibovich, M. L. Blute, J. C. Cheville, and G. Vasmatzis Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness Clin. Cancer Res., July 15, 2005; 11(14): 5128 - 5139. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-T. Lin, C.-C. Chang, S.-T. Chen, H.-L. Chang, J.-L. Su, Y.-P. Chau, and M.-L. Kuo Cyr61 Expression Confers Resistance to Apoptosis in Breast Cancer MCF-7 Cells by a Mechanism of NF-{kappa}B-dependent XIAP Up-Regulation J. Biol. Chem., June 4, 2004; 279(23): 24015 - 24023. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |